Skip to main content
S 1355 118th Congress Senate Health Administrative law and regulatory procedures Advanced technology and technological innovations Advisory bodies Appropriations Department of Health and Human Services Drug therapy Executive agency funding and structure Government information and archives Government studies and investigations Health information and medical records Infectious and parasitic diseases Medical research Prescription drugs Public contracts and procurement Research and development

PASTEUR Act of 2023

Introduced: April 27, 2023 Introduced by: Bennet, Michael F. Democratic · Colorado See on congress.gov
This bill died when the 118th Congress ended
It never became law before the 118th Congress (2023–2024) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 27, 2023
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Apr 27, 2023
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act of 2023 or the PASTEUR Act of 2023

This bill authorizes the Department of Health and Human Services (HHS) to enter into subscription contracts for critical-need antimicrobial drugs, provides $6 billion in appropriations for activities under the bill, and contains other related provisions.

A manufacturer of a Food and Drug Administration-approved antimicrobial drug may apply to HHS to have the drug designated as a critical-need antimicrobial, and HHS may enter into a subscription contract for such a critical-need antimicrobial. The bill imposes certain requirements related to such contracts, including a mechanism to lower payments under the contract in certain instances to limit the manufacturer's revenue from the drug.

Furthermore, HHS and the Centers for Disease Control and Prevention (CDC) shall award grants to support efforts to encourage the appropriate use of antimicrobial drugs and efforts to combat antimicrobial resistance. The CDC shall also track and assess data relating to antibacterial resistance and human antibiotic use and make such data publicly available.

HHS shall also establish a Committee on Critical Need Antimicrobials. The committee shall develop a list of prioritized infections for which new antimicrobial drug development is needed, among other duties.

Within six years of the bill's enactment, the Government Accountability Office shall report to Congress a study on the bill's effectiveness in developing priority antimicrobial drugs.

What's happening now April 27, 2023

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Related & companion bills 1
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Lobbying activity 6

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

Cite this page click to expand
APA
U.S. Congress. (2026). S. 1355: PASTEUR Act of 2023. 118th Congress. Open America. https://openamerica.io/bill/118-S-1355/
MLA
"S. 1355: PASTEUR Act of 2023." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-S-1355/.
Bluebook (legal)
S. 1355, 118th Cong. (2026), https://openamerica.io/bill/118-S-1355/.
Markdown link
[S. 1355: PASTEUR Act of 2023](https://openamerica.io/bill/118-S-1355/)
Report a problem